Teleflex (NYSE:TFX) Given a $130.00 Price Target by Royal Bank Of Canada Analysts

Royal Bank Of Canada set a $130.00 price target on Teleflex (NYSE:TFX - Free Report) in a report issued on Tuesday morning, MarketBeat reports. The brokerage currently has a sector perform rating on the medical technology company's stock.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company cut their target price on Teleflex from $146.00 to $137.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Mizuho set a $155.00 target price on Teleflex in a research report on Wednesday, April 16th. Wall Street Zen lowered Teleflex from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Morgan Stanley cut their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Finally, Truist Financial cut their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Teleflex has a consensus rating of "Hold" and a consensus price target of $159.63.

Teleflex Trading Down 2.1%

Shares of TFX stock traded down $2.41 on Tuesday, hitting $111.18. The company had a trading volume of 845,808 shares, compared to its average volume of 637,431. The firm has a market cap of $4.91 billion, a P/E ratio of 35.07, a P/E/G ratio of 1.78 and a beta of 1.08. The stock's 50-day moving average is $120.99 and its two-hundred day moving average is $141.97. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.32 and a current ratio of 2.28. Teleflex has a twelve month low of $110.86 and a twelve month high of $249.91.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.03. The company had revenue of $700.67 million during the quarter, compared to analysts' expectations of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The business's quarterly revenue was down 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.21 earnings per share. On average, equities research analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Stockholders of record on Tuesday, May 20th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.22%. The ex-dividend date was Tuesday, May 20th. Teleflex's dividend payout ratio (DPR) is presently 42.90%.

Institutional Trading of Teleflex

A number of institutional investors and hedge funds have recently modified their holdings of TFX. Proficio Capital Partners LLC purchased a new stake in shares of Teleflex during the fourth quarter valued at approximately $3,297,000. Raymond James Financial Inc. purchased a new stake in shares of Teleflex during the fourth quarter valued at approximately $10,342,000. HighTower Advisors LLC increased its position in shares of Teleflex by 24.3% during the fourth quarter. HighTower Advisors LLC now owns 4,969 shares of the medical technology company's stock valued at $884,000 after acquiring an additional 971 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Teleflex by 4.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 4,670 shares of the medical technology company's stock valued at $831,000 after acquiring an additional 215 shares during the last quarter. Finally, Cibc World Markets Corp increased its position in Teleflex by 14.4% in the fourth quarter. Cibc World Markets Corp now owns 7,340 shares of the medical technology company's stock worth $1,306,000 after buying an additional 925 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.